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Abstract
Cancer immunotherapy has gained significant momentum from recent clinical successes of checkpoint blockade
inhibition. Massively parallel sequence analysis suggests a connection between mutational load and response to
this class of therapy. Methods to identify which tumor-specific mutant peptides (neoantigens) can elicit anti-tumor
T cell immunity are needed to improve predictions of checkpoint therapy response and to identify targets for
vaccines and adoptive T cell therapies. Here, we present a flexible, streamlined computational workflow for
identification of personalized Variant Antigens by Cancer Sequencing (pVAC-Seq) that integrates tumor mutation
and expression data (DNA- and RNA-Seq). pVAC-Seq is available at https://github.com/griffithlab/pVAC-Seq.
Background
Boon et al. were the first to demonstrate that cancer-
specific peptide/MHC class 1 complexes could be recog-
nized by CD8+ T cells present in cancer patients [1].
Substantial evidence now suggests that anti-tumor T
cells recognize tumor somatic mutations, translated as
single amino acid substitutions, as ‘neoantigens’. These
unique antigenic markers arise from numerous genetic
changes, acquired somatically that are present exclu-
sively in tumor (mutant) and not in normal (wild-type
(WT)) cells [2]. Recent preclinical data indicate that
these mutated proteins, upon processing and presenta-
tion in the context of MHC molecules expressed by
antigen-presenting cells, can be recognized as ‘non-self ’
by the immune system.
Our previous work in murine sarcoma models was
one of the first demonstrations of how somatic cancer
mutations could be identified from massively parallel se-
quencing, and when considered in the context of MHC
binding affinity, can predict tumor specific neoantigens
[3]. A subsequent study further demonstrated that these
neoantigens were the same epitopes recognized by anti-
PD1 and anti-CTLA4 checkpoint blockade therapies and
that peptide vaccines comprising neoantigens could pro-
vide prophylactic effects [4]. Several other studies have
also characterized these neoantigens as being derived
from somatically mutated genes in mouse [5] as well as
in humans [6–9], and have shown that they can be rec-
ognized by T cells.
While checkpoint blockade therapies have achieved tre-
mendous success in the clinic, patient-specific vaccines
still meet a clinical need in those patients that either do
not respond, develop resistance, or cannot tolerate the as-
sociated side effects of checkpoint blockade drugs. The
main paradigm behind the development of cancer vac-
cines rests on the assumption that if the immune system
is stimulated to recognize neoantigens, it may be possible
to elicit the selective destruction of tumor cells. Vaccines
incorporate these neoantigen peptides with the aim of
enhancing the immune system’s anti-tumor activity by
selectively increasing the frequency of specific CD8+ T
cells, and hence expanding the immune system’s ability
to recognize and destroy cancerous cells. This process
is dependent on the ability of these peptides to bind
and be presented by HLA class I molecules, a critical
step to inducing an immune response and activating
CD8+ T cells [10].
As we move from vaccines targeting ‘shared’ tumor anti-
gens to a more ‘personalized’ medicine approach, in silico
strategies are needed to first identify, then determine
which somatic alterations provide the optimal neoantigens
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for the vaccine design. Ideally, an optimal strategy would
intake mutation calls from massively parallel sequencing
data comparisons of tumor to normal DNA, identify the
neoantigens in the context of the patient’s HLA alleles,
and parse out a list of optimal peptides for downstream
testing. At present, elements of this ideal strategy exist,
but are not available as open source code to permit others
to adopt these methods into cancer care strategies. This
manuscript describes one such approach, and provides a
link to open source code for end users.
For example, to optimize identification and selection
of vaccine neoantigens, several in silico epitope binding
prediction methods have been developed [11–15]. These
methods employ various computational approaches such
as Artificial Neural Networks (ANN) and Support Vector
Machines (SVM) and are trained on binding to different
HLA class I alleles to effectively identify putative T cell
epitopes.
There are also existing software tools (IEDB [16],
EpiBot [17], EpiToolKit [18]) that compile the results
generated from individual epitope prediction algo-
rithms to improve the prediction accuracy with consen-
sus methods or a unified final ranking. The current
implementation of EpiToolKit (v2.0) also has the added
functionality of incorporating sequencing variants in its
Galaxy-like epitope prediction workflow (via its Poly-
morphic Epitope Prediction plugin). However, it does not
incorporate sequence read coverage or gene expression in-
formation available from massively parallel sequencing
datasets, nor can it compare the binding affinity of the
peptide in the normal sample (WT) versus the tumor
(mutant). Another multi-step workflow Epi-Seq [19] uses
only raw RNA-Seq tumor sample reads for variant calling
and predicting tumor-specific expressed epitopes.
We report herein an open source method called pVAC-
Seq that we developed to address the critical need for a
workflow that assimilates and leverages massively parallel
DNA and RNA sequencing data to systematically identify
and shortlist candidate neoantigen peptides from a tu-
mor’s mutational repertoire that could potentially be used
in a personalized vaccine after immunological screening.
This automated analysis offers the functionality to com-
pare and differentiate the epitopes found in normal cells
against the neoepitopes specifically present in tumor cells
for use in personalized cancer vaccines, and the flexibility
to work with any user-specified list of somatic variants.
Preliminary versions of this pipeline were applied in
mouse models of cancer to identify expressed mutations
in cancer cells and characterize tumor-specific mutant
peptides that drive T cell-mediated tumor rejection in
mice with MCA-induced sarcomas [3, 4]. More recently,
we used this pipeline in a proof-of-concept trial in melan-
oma patients, to identify the neoantigen peptides for use
in dendritic cell-based personalized vaccines [20].
Methods
Our in silico automated pipeline for neoantigen predic-
tion (pVAC-Seq) requires several types of data input
from next-generation sequencing assays. First, the
pVAC-Seq pipeline requires a list of non-synonymous
mutations, identified by a somatic variant-calling pipe-
line. Second, this variant list must be annotated with
amino acid changes and transcript sequences. Third,
the pipeline requires the HLA haplotypes of the patient,
which can be derived through clinical genotyping assays
or in silico approaches. Having the above-mentioned
required input data in-hand, pVAC-Seq implements
three steps: performing epitope prediction, integrating
sequencing-based information, and, lastly, filtering
neoantigen candidates. The following paragraphs de-
scribe the analysis methodology from preparation of in-
puts to the selection of neoantigen vaccine candidates
via pVAC-Seq (Fig. 1).
Prepare input data: HLA typing, alignment, variant
detection, and annotation
As described above, pVAC-Seq relies on input gener-
ated from the analysis of massively parallel sequencing
data that includes annotated non-synonymous somatic
variants that have been ‘translated’ into mutant amino
acid changes, as well as patient-specific HLA alleles.
Importantly, these data can be obtained from any ap-
propriate variant calling, and annotation pipeline and
HLA typing approach. Here, we outline our preparatory
steps to generate these input data [20]. Somatic variant
analysis of exome sequencing datasets was performed
using the Genome Modeling System (GMS) [21] for align-
ment and variant calling. In brief, BWA (version 0.5.9)
[22] was used for alignment with default parameters, ex-
cept that the number of threads was set to 4 (-t 4) for
faster processing, and the quality threshold for read trim-
ming to 5 (-q 5). The resulting alignments were de-
duplicated via Picard MarkDuplicates (version 1.46) [23].
In cases where clinically genotyped HLA haplotyping
calls were not available, we used in silico HLA typing
by HLAminer (version 1) [24] or by Athlates [25]. HLA
typing was performed on the normal (peripheral blood
mononuclear cells), rather than the tumor sample.
Though the two software tools were >85% concordant
in our test data (unpublished data), it is helpful to use
both algorithms in order to break ties reported by
HLAminer (see below).
I. HLAminer for in silico HLA-typing using Whole
Genome Sequencing (WGS) data: When predicting
HLA class I alleles from WGS data, we used HLA-
miner in de novo sequence alignment mode [26] by
running the script HPTASRwgs_classI.sh, provided
in the HLAminer download, with default
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parameters. (The download includes detailed in-
structions for customizing this script, and the scripts
on which it depends, for the user’s computing envir-
onment.) For each of the three HLA loci, HLAminer
reports predictions ranked in decreasing order by
score, where ‘Prediction #1’ and ‘Prediction #2’ are the
most likely alleles for a given locus. When ties were
present for Prediction 1 or Prediction 2, we used all
tied predictions for downstream neoepitope
prediction. However, it should be noted that most
epitope prediction algorithms, including NetMHC
[13, 14], only work with an algorithm-specific subset
of HLA alleles, so we are constrained to the set of
NetMHC-compatible alleles. The current version
NetMHC v3.4 supports 78 human alleles.
II. Athlates for in silico HLA-typing using exome
sequence data: We diverged from the recommended
Athlates protocol at two points: (1) We performed
Fig. 1 Overview of the pipeline pVAC-Seq: This figure illustrates the methodological framework behind the pVAC-Seq pipeline. Starting with
preparation of inputs, it consists of three main steps - epitope prediction, integration of sequencing information, and filtered candidate selection
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the alignment step, in which exome sequence data
from the normal tissue sample are aligned against
reference HLA allele sequences present in the
IMGT/HLA database [27], using BWA with zero
mismatches (params : bwa aln -e 0 -o 0 -n 0) instead
of NovoAlign [28] with one mismatch. (2) In the
subsequent step, sequence reads that matched, for
example, any HLA-A sequence from the database
were extracted from the alignment using bedtools
[29] instead of Picard. This procedure is resource-
intensive, and may require careful resource
management. Athlates reports alleles that have a
Hamming distance of at most 2 and meet several
coverage requirements. Additionally, it reports
‘inferred allelic pairs’, which are identified by
comparing each possible allelic pair to a longer list
of candidate alleles using a Hamming distance-based
score. We typically used the inferred allelic pair as
input to subsequent steps in the neoepitope prediction
pipeline.
After alignments (and optional HLA typing) were com-
pleted, somatic mutation detection was performed using
the following series of steps (Additional file 1: Figure S1):
(1) Samtools [30, 31] mpileup v0.1.16 was run with param-
eters ‘-A -B’ with default setting for the other parameters.
These calls were filtered based on GMS ‘snp-filter v1’ and
were retained if they met all of the following rules: (a) Site
is greater than 10 bp from a predicted indel of quality 50
or greater; (b) The maximum mapping quality at the site
is ≥40; (c) Fewer than three single-nucleotide variants
(SNV) calls are present in a 10 bp window around the site;
(d) The site is covered by at least three reads and less than
1 × 109 reads; and (e) Consensus and SNP quality is ≥20.
The filtered Samtools variant calls were intersected with
those from Somatic Sniper [32] version 1.0.2 (params: -F
vcf q 1 -Q 15), and were further processed through the
GMS ‘false-positive filter v1’ (params: –bam-readcount-
version 0.4 –bamreadcount-min-base-quality 15 –min-
mapping-quality 40 –min-somatic-score 40). This filter
used the following criteria for retaining variants: (a) ≥1%
of variant allele support must come from reads sequenced
on each strand; (b) variants must have ≥5% Variant Allele
Fraction (VAF); (c) more than four reads must support
the variant; (d) the average relative distance of the variant
from the start/end of reads must be greater than 0.1; (e)
the difference in mismatch quality sum between variant
and reference reads must be less than 50; (f) the difference
in mapping quality between variant and reference reads
must be less than 30; (g) the difference in average support-
ing read length between variant and reference reads must
be less than 25; (h) the average relative distance to the ef-
fective 3’ end of variant supporting reads must be at least
0.2; and (i) the variant must not be adjacent to five or
more bases of the same nucleotide identity (for example, a
homopolymer run of the same base). (2) VarScan Somatic
version 2.2.6 [33, 34] was run with default parameters and
the variant calls were filtered by GMS filter ‘varscan-high-
confidence filter version v1’. The ‘varscan-high-confidence
v1’ filter employed the following rules to filter out variants:
(a) P value (reported by Varscan) is greater than 0.07; (b)
Normal VAF is greater than 5%; (c) Tumor VAF is less
than 10%; or (d) less than two reads support the variant.
The remaining variant calls were then processed through
false-positive filter v1 (params: –bam-readcount-version
0.4 –bamreadcount-min-base-quality 15) as described
above. (3) Strelka version 1.0.10 [35] (params: isSkip-
DepthFilters = 1).
Our GMS pipeline expects a matched normal sample
for filtering out potentially rare germline variants.
However, in the absence of a matched normal tissue,
the dbSNP and 1000 Genome databases could be used
for filtering these variants.
The consolidated list of somatic mutations identified
from these different variant-callers was then annotated
using our internal annotator as part of the GMS pipeline.
This annotator leverages the functionality of the Ensembl
database [36] and Variant Effect Predictor (VEP) [37].
We wish to emphasize that any properly formatted list
of annotated variants can be used as input to subsequent
steps in the pipeline. From the annotated variants, there
are two critical components that are needed for pVAC-
Seq: amino acid change and transcript sequence. Even a
single amino acid change in the transcript arising from
missense mutations can alter the binding affinity of the
resulting peptide with the HLA class I molecule and/or
recognition by the T cell receptor. Larger insertions and
deletions like those arising from frameshift and truncat-
ing mutations, splicing aberrations, gene fusions, and so
on may also result in potential neoantigens. However,
for this initial version of pVAC-Seq, we chose to focus
our analysis on only missense mutations.
One of the key features of our pipeline is the ability to
compare the differences between the tumor and the nor-
mal peptides in terms of the peptide binding affinity.
Additionally, it leverages RNA-Seq data to incorporate
isoform-level expression information and to quickly cull
variants that are not expressed in the tumor. To easily
integrate RNA-Seq data, both transcript ID as well as
the entire WT transcript amino acid sequence is needed
as part of the annotated variant file.
Perform epitope prediction
One of the key components of pVAC-Seq is predicting
epitopes that result from mutations by calculating their
binding affinity against the HLA class I molecule. This
process involves the following steps for effectively prepar-
ing the input data as well as parsing the output (Fig. 2).
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Generate FASTA file of peptide sequences
Peptide sequences are a key input to the MHC binding
prediction tool, and the existing process to efficiently
compare the germline normal with the tumor is very
onerous. To streamline the comparison, we first build a
FASTA file that consists of two amino acid sequences
per variant site: WT (normal) and mutant (tumor). The
FASTA sequence is built using approximately eight to 10
flanking amino acids on each side of the mutated amino
acid. However, if the mutation is towards the end or be-
ginning of the transcript, then the preceding or succeed-
ing 16 to 20 amino acids are taken, respectively, as
needed, to build the FASTA sequence. Subsequently, a
key file is created with the header (name and type of
variant) and order of each FASTA sequence in the file.
This is done to correlate the output with the name of
the variant protein, as subsequent epitope prediction
software strips off each FASTA header.
Run epitope prediction software
Previous studies [38, 39] have shown that allele-specific
epitope prediction software, such as NetMHC, perform
slightly better when compared to pan-specific methods
such as NetMHCpan [40–42] in case of well-
characterized alleles due to availability of large amounts of
training data. However, pan-specific methods could be
beneficial in cases where there is limited peptide binding
data for training, for arbitrary HLA molecules, or when
predicting epitopes for non-human species. We do
anticipate adding this support for additional softwares in
upcoming versions of pVAC-Seq. To predict high affinity
peptides that bind to the HLA class I molecule, currently
only the standalone version of NetMHC v3.4 is supported.
The input to this software is the HLA class I haplotype of
the patient, determined via genotyping or using in silico
methods, as well as the FASTA file generated in the previ-
ous step comprising mutated and WT 17-21-mer
(a) (b)
(c) (d)
Fig. 2 Generation of peptide sequences and filtering predicted epitope candidates. a Amino acid FASTA sequence is built using 10 flanking
amino acids on each side of the mutated amino acid. The preceding or succeeding 20 amino acids are taken if the mutation lies near the end or
beginning of the transcript, respectively. b All predicted candidate peptides from epitope prediction software based on selected k-mer window
size. c Only localized peptides (those containing the mutant amino acid) are considered to compare to WT counterpart. d The ‘best candidate’
(lowest MT binding score) per mutation is chosen across all specified k-mers and between all independent HLA allele types that were used
as input
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sequences. Typically, antigenic epitopes presented by
HLA class I molecules can vary in length and are in the
range of eight to 11 amino acids (aa). Hence, we recom-
mend specifying the same range when running epitope
prediction software.
Parse and filter the output
Starting with the output list of all possible epitopes
from the epitope prediction software, we apply specific
filters to choose the best candidate mutant peptides.
First, we restrict further consideration to strong- to
intermediate-binding peptides by focusing on candi-
dates with a mutant (MT) binding score of less than
500 nM. Second, epitope binding calls are evaluated
only for those peptides that contain the mutant amino
acid (localized peptides). This filter eliminates any WT
peptides that may overlap between the two FASTA se-
quences. Our workflow enables screening across mul-
tiple lengths and multiple alleles very efficiently. If
predictions are run to assess multiple epitope lengths
(for example, 9-mer, 10-mer, and so on), and/or to
evaluate all patient’s HLA-A, -B, and -C alleles, we re-
view all localized peptides and choose the single best
binding value representative across lengths (9 aa, 10 aa,
and so on) based on lowest binding score for MT se-
quence. Furthermore, we choose the ‘best candidate’
(lowest MT binding score) per mutation between all in-
dependent HLA alleles that were used as input. Add-
itionally, in the output file, the WT peptide binding
score is provided. Although this score may not directly
affect candidate choice or immunogenicity, end users
may find this comparative information useful.
Integrate expression and coverage information
We subsequently apply several filters to ensure we are
predicting neoantigens that are expressed as RNA vari-
ants, and that have been predicted correctly based on
coverage depth in the normal and tumor tissue datasets.
We have found that gene expression levels from RNA-
Seq data, measured as fragments per kilobase of exon
per million reads mapped (FPKM), provide a good
method to filter only the expressed transcripts. We used
the tuxedo suite - Tophat [43, 44] and Cufflinks [45] - as
part of the GMS to align RNA-Seq data and subse-
quently infer gene expression for our in-house sequen-
cing data. Depending on the type of RNA prep kit,
Ovation® RNA-Seq System V2 (NuGEN Technologies,
Inc., San Carlos, CA, USA) or TruSeq Stranded Total
RNA Sample Prep kit (Illumina, Inc., San Diego, CA,
USA) used, Tophat was run with the following parame-
ters: Tophat v2.0.8 ‘–bowtie-version = 2.1.0’ for Ovation,
and ‘–library-type fr-firststrand –bowtie-version = 2.1.0’
for Truseq. For Ovation data, prior to alignment, paired
2 × 100bp sequence reads were trimmed with Flexbar
version 2.21 [46] (params: –adapter CTTTGTGTTTGA
–adapter-trim-end LEFT –nono-length-dist –threads 4
–adapter-min-overlap 7 –maxuncalled 150 –min-read-
length 25) to remove single primer isothermal amplifica-
tion adapter sequences. Expression levels (FPKM) were
calculated with Cufflinks v2.0.2 (params: –max-bundle-
length = 10000000 –num-threads 4).
For selecting unique vaccine candidates, targeting the
best ‘quality’ mutations is an important factor for priori-
tizing peptides. Sequencing depth as well as the fraction
of reads containing the variant allele (VAF) are used as
criteria to filter or prioritize mutations. This information
was added in our pipeline via bam-readcount [47]. Both
tumor (from DNA as well as RNA) and normal coverage
are calculated along with the VAF from corresponding
DNA and RNA-Seq alignments.
Filter neoepitope candidates
Since manufacturing antigenic peptides is one of the
most expensive steps in vaccine development and effi-
cacy depends on selection of the best neoantigens, we
filter the list of predicted high binding peptides to the
most highly confident set, primarily with expression
and coverage based filters. The pVAC-Seq pipeline per-
mits user-specified filters, and we encourage new users
to experiment with these cutoffs in order to tailor the
pipeline to their input data and analysis needs. We
employ the following filters: (a) Depth based filters: We
filter out any variants with normal coverage <=5× and
normal VAF of >=2%. The normal coverage cutoff can
be increased up to 20× to eliminate occasional mis-
classification of germline variants as somatic. Similarly,
the normal VAF cutoff can be increased based on sus-
pected level of contamination by tumor cells in the nor-
mal sample.
For tumor coverage from DNA and/or RNA, a cutoff
is placed at >=10× with a VAF of >=40%. This ensures
that neoantigens from the founder clone in the tumor
are included, but the tumor VAF can be lowered to cap-
ture more variants, which are less likely to be present in
all tumor cells. Alternatively, if the patients are selected
based on a pre-existing disease-associated mutation such
as BRAF V600E in the case of melanoma, the VAF of
the specific presumed driver mutation can be used as a
guide for assessing clonality of other mutations. Also,
other known driver mutations such as KRAS G12/G13
or NRAS Q61 may be used to determine purity, and to
subsequently adjust the VAF filters to target founder
clone mutations. (b) Expression based filters: As a
standard, genes with FPKM values greater than zero are
considered to be expressed. We slightly increase this
threshold to 1, to eliminate noise. Alternatively, we
analyze the FPKM distribution (and the corresponding
standard deviation) over the entire sample, to determine
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the sample-specific cutoffs for gene expression. Spike-
in controls may also be added to the RNA-Seq
experiment to assess quality of the sequencing library
and to normalize gene expression data. Since alterna-
tive splicing can give rise to multiple transcripts that
encompass the variant residue, optionally, all these
transcripts could be included in analysis during the
annotation step. However, one should be careful as
this could potentially give rise to transcripts that do
not include the variant. Also, long transcripts or tran-
scripts with high G/C content might show some bias
if RNA-CapSeq is used but in our experience are
generally well represented. The primary goal of using
RNA-(Cap)Seq data in our method is to address to
questions of primary importance: (1) is the gene
expressed at a reasonably high level (for example,
FPKM >1); and (2) is the variant allele expressed in
the RNA-seq fragment population.
This filtered list of mutations is manually reviewed via
visual inspection of aligned reads in a genome viewer
like IGV [48, 49] to reduce the retention of obvious false
positive mutations.
Dataset
To demonstrate the workings of our in silico pVAC-Seq
pipeline, we applied it to four metastatic melanoma
patients, the clinical results for three of whom were
described previously [20]. In brief, there were three
patients (MEL21, MEL38, MEL218) with stage III
resected cutaneous melanoma, all of whom had received
prior treatment with ipilimumab, and one patient
(MEL69) with stage IV cutaneous melanoma. All four
patients were enrolled in a phase 1 vaccine clinical trial
(NCT00683670, BB-IND 13590) employing autologous,
functionally mature, interleukin (IL)-12p70-producing
dendritic cells (DC). Informed consent for genome
sequencing and data sharing was obtained for all
patients on a protocol approved by the Institutional
Review Board of Washington University. We performed
genomic analysis of their surgically excised tumors to
select candidates for the personalized DC vaccine. Three
of these patients (MEL21, MEL38, MEL69) had multiple
metachronous tumors. Exome sequencing as well as
RNA-CapSeq was performed for each of these tumors,
and their corresponding matched normal tissue. The
raw exome and transcriptome sequence data are avail-
able on the Sequence Read Archive database: Bioproject
PRJNA278450, and corresponding dbGaP accession:
phs001005.
Results and Discussion
Since melanoma patients harbor hundreds of mutations,
it can be challenging to filter down and target the best
set of potentially immunogenic neoantigens for vaccine
design. For each of the four metastatic melanoma pa-
tients, we used the annotated list of SNVs generated
using the GMS strategy described above, and analyzed
them via our pVAC-Seq pipeline. As mentioned earlier,
for the demonstration of this workflow, amino acid
changes resulting from only missense mutations were
considered for analysis. Table 1 shows the breakdown of
these SNVs described previously [20] and the data gener-
ated in subsequent steps through our workflow, leading to
a high-confidence list of neoepitopes. As part of our local
workflow, NetMHC v3.4 was used as the epitope predic-
tion software to generate HLA class I restricted epitopes.
As is evident from Table 1, there were multitudes of epi-
topes reported by NetMHC v3.4 in its raw format. This
number increased even further with the addition of each
HLA class I allele. Using pVAC-Seq, and its recommended
thresholds for filtering (binding and coverage-based), we
were able to produce a more reasonable list of high affin-
ity HLA class I binding neoantigen candidates for experi-
mental validation.
These candidate neoantigens were experimentally
tested in binding assays and those with confirmed bind-
ing to HLA class I restricting molecules were incorpo-
rated in the vaccine formulation [20]. Since all of these
patients harbor the BRAF V600E mutation, we used its
VAF in each sample as a comparative control of tumor
purity and clonality. Integration of variant coverage in-
formation from Exome and RNA-Seq (VAF), as well as
mutant expression information (FPKM), provided add-
itional information needed to make an informed deci-
sion on the number and identity of peptides to include
in each patient-specific vaccine (Fig. 3, Additional file 2:
Figure S2, Additional file 3: Figure S3, and Additional
file 4: Figure S4).
As shown, if existing epitope prediction software
tools were solely used to generate neoantigen predic-
tions in these patients, it would have been challenging
to integrate the filters as well as the important digital
sequencing metrics that ultimately determined the
‘quality’ of these candidates. By implementing the novel
methods reported in this manuscript, we were able to
rapidly streamline the screening and identification of a
smaller number of potentially immunogenic neoepitopes
within the landscape of all neoepitopes. This method can
be further extended to include other genomic alterations
such as frame-shift insertions and deletions, splicing
aberrations, and gene fusions, which may in some cases
cause larger changes in epitope binding affinities. We are
currently testing approaches to include binding predic-
tions from frame-shift insertions and deletions by incorp-
orating VEP annotation, and once tested, will be adding
this functionality to the github repository for pVAC-Seq.
By expanding the focus from just somatic point mutations
to the entire neoantigen landscape, it may also be possible
Hundal et al. Genome Medicine  (2016) 8:11 Page 7 of 11
Table 1 Summary of predicted epitope candidates through pVAC-Seq pipeline
MEL21 MEL38 MEL218 MEL69
LN Skin Skin Axilla Breast AbWall LN Skin / Limb Skin / Scalp
(2011) (2012) (2013) (2012) (2013) (2013) (2005) (2013) (2013)
Total SNVs 702 838 1099 359 402 385 695 256 282
Missense SNVs 443 515 598 219 247 238 437 141 162
21-mer FASTA entries (WT & MT) 856 1,004 1,002 424 482 462 850 272 314






























































Filter 1: Binding based 110 121 144 103 112 111 161 50 65
HLA-A02:01 candidates only 79 96 111 52 48 46 93 25 34
Filter 2: Manually reviewed HLA-A02:01
candidates (Exome plus RNA-Seq)
11 11 12 14 16 16 24 6 12
Filter 3: Experimentally tested 16 14 18 12
Filter 4: Vaccine tested 7 7 7 10
Immunogenicity 3 3 3 4
The table illustrates the number of raw candidates predicted by NetMHC, and the parsing and filtering strategies applied thereafter to the final list of neoantigen candidates. These candidates were then













to better assess whether neoantigen load itself can serve
as a biomarker for prediction of checkpoint blockade
response.
Conclusions
The current regimen for predicting and screening
neoantigens from sequencing data is laborious and in-
volves a large number of intermediate steps such as cre-
ating FASTA files, running the prediction algorithms
(most of the time online), and filtering output for high
binding affinity candidates. Our flexible, automated in
silico workflow, pVAC-Seq, provides higher efficiency
and faster turnaround by automating many of these
steps. This approach should help to evaluate tumor-
specific neoepitopes in a much-reduced time, thereby in-
creasing its applicability for clinical use. As we learn
from ongoing early mouse and human trials, the
methods developed will help optimize the composition
of personalized cancer vaccines with high precision and
will expedite vaccine design to address growing clinical
demand.
Additional files
Additional file 1: Figure S1. Illustrates the variant calling pipeline
employed as part of the GMS strategy. (PDF 150 kb)
Additional file 2: Figure S2. Illustrates the landscape of neoantigen
vaccine candidates in patient MEL38 after being prioritized using the
pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well
log2 fold change, calculated as the ratio of WT binding affinity over mutant
binding affinity. Recommended exome and RNA VAF cutoffs are also
indicated. Candidates that were incorporated in the vaccine are labeled
based on the genes containing these somatic mutations. Red boxes depict
naturally occurring (that is, pre-existing T cell response) and blue boxes
denote vaccine-induced neoantigens that were recognized by T cells.
Since BRAF was used as a guide for assessing clonality of other
mutations, it is also shown in each of three metachronous tumors (from
the same patient). (PDF 182 kb)
Additional file 3: Figure S3. Illustrates the landscape of neoantigen
vaccine candidates in patient MEL218 after being prioritized using the
pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well
log2 fold change, calculated as the ratio of WT binding affinity over mutant
binding affinity. Recommended exome and RNA VAF cutoffs are also indicated.
Candidates that were incorporated in the vaccine are labeled based on the
genes containing these somatic mutations. Red boxes depict naturally occurring
(that is, pre-existing T cell response) and blue boxes denote vaccine-induced
Fig. 3 Landscape of filtered neoantigen candidates. This figure illustrates the landscape of neoantigen vaccine candidates in patient MEL21 after
being prioritized using the pVAC-Seq pipeline. The points represent the overall sequencing information: exome and RNA VAFs, gene expression
in terms of log2 FPKM value, as well log2 fold change, calculated as the ratio of WT binding affinity over mutant binding affinity. Recommended
exome and RNA VAF cutoffs are also indicated. Candidates that were incorporated in the vaccine are labeled based on the genes containing
these somatic mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and blue boxes denote vaccine-induced
neoantigens that were recognized by T cells. Since BRAF was used as a guide for assessing clonality of other mutations, it is also shown in each
of three metachronous tumors (from the same patient)
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neoantigens that were recognized by T cells. Since BRAF was used as a guide
for assessing clonality of other mutations, it is also shown. (PDF 111 kb)
Additional file 4: Figure S4. Illustrates the landscape of neoantigen
vaccine candidates in patient MEL69 after being prioritized using the
pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAF cutoffs, gene expression in terms of log2 FPKM value,
as well log2 fold change, calculated as the ratio of WT binding affinity over
mutant binding affinity. Recommended exome and RNA VAFs are also
indicated. Candidates that were incorporated in the vaccine are labeled
based on the genes containing these somatic mutations. Red boxes depict
naturally occurring (that is, pre-existing T cell response) and blue boxes
denote vaccine-induced neoantigens that were recognized by T cells. Since
BRAF was used as a guide for assessing clonality of other mutations, it
is also shown in both the metachronous tumors (from the same pa-
tient). (PDF 143 kb)
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